Intuvax: Phase I/II data

Data from 2 patients with poor prognosis in a Swedish Phase I/II trial showed that Intuvax led to an average survival of about 14 months. Immunicum said the expected median survival is 5 months in untreated patients and 8 months patients treated with existing therapies such as Sutent sunitinib. The trial enrolled 12 patients to receive 2 intratumoral injections of Intuvax every 2 weeks followed by surgical resection of the cancerous kidney. No serious Intuvax-related adverse events have been recorded and no patients have died. ...